Suppr超能文献

侵袭性腺瘤和垂体癌:SEER 数据库分析。

Invasive adenoma and pituitary carcinoma: a SEER database analysis.

机构信息

Department of Radiation Oncology, Indiana University School of Medicine, Indianapolis, IN, 46202, USA.

出版信息

Neurosurg Rev. 2014 Apr;37(2):279-85; discussion 285-6. doi: 10.1007/s10143-014-0525-y. Epub 2014 Feb 14.

Abstract

Invasive pituitary adenomas and pituitary carcinomas are clinically indistinguishable until identification of metastases. Optimal management and survival outcomes for both are not clearly defined. The purpose of this study is to use the Surveillance, Epidemiology, and End Results (SEER) database to report patterns of care and compare survival outcomes in a large series of patients with invasive adenomas or pituitary carcinomas. One hundred seventeen patients diagnosed between 1973 and 2008 with pituitary adenomas/adenocarcinomas were included. Eighty-three invasive adenomas and seven pituitary carcinomas were analyzed for survival outcomes. Analyzed prognostic factors included age, sex, race, histology, tumor extent, and treatment. A significant decrease in survival was observed among carcinomas compared to invasive adenomas at 1, 2, and 5 years (p = 0.047, 0.001, and 0.009). Only non-white race, male gender, and age ≥65 were significant negative prognostic factors for invasive adenomas (p = 0.013, 0.033, and <0.001, respectively). There was no survival advantage to radiation therapy in treating adenomas at 5, 10, 20, or 30 years (p = 0.778, 0.960, 0.236, and 0.971). In conclusion, pituitary carcinoma patients exhibit worse overall survival than invasive adenoma patients. This highlights the need for improved diagnostic methods for the sellar phase to allow for potentially more aggressive treatment approaches.

摘要

侵袭性垂体腺瘤和垂体腺癌在未发现转移灶之前临床难以区分。目前尚未明确这两种肿瘤的最佳治疗方法和生存结局。本研究旨在利用监测、流行病学和最终结果(SEER)数据库报告一组侵袭性垂体腺瘤或垂体腺癌患者的治疗模式,并比较其生存结局。共纳入 1973 年至 2008 年间诊断为垂体腺瘤/腺癌的 117 例患者。对 83 例侵袭性垂体腺瘤和 7 例垂体腺癌患者的生存结局进行分析。分析的预后因素包括年龄、性别、种族、组织学、肿瘤范围和治疗方法。与侵袭性垂体腺瘤相比,腺癌患者在 1、2 和 5 年的生存率显著降低(p=0.047、0.001 和 0.009)。非白人种族、男性和年龄≥65 岁是侵袭性垂体腺瘤的显著负性预后因素(p=0.013、0.033 和<0.001)。在 5、10、20 和 30 年时,放射治疗对治疗侵袭性垂体腺瘤并没有生存优势(p=0.778、0.960、0.236 和 0.971)。总之,垂体腺癌患者的总体生存率明显低于侵袭性垂体腺瘤患者。这突出表明需要改进鞍区诊断方法,以便能够采取更积极的治疗方法。

相似文献

1
Invasive adenoma and pituitary carcinoma: a SEER database analysis.侵袭性腺瘤和垂体癌:SEER 数据库分析。
Neurosurg Rev. 2014 Apr;37(2):279-85; discussion 285-6. doi: 10.1007/s10143-014-0525-y. Epub 2014 Feb 14.

引用本文的文献

3
4
Prognostic Biomarkers in Pituitary Tumours: A Systematic Review.垂体肿瘤的预后生物标志物:一项系统综述
touchREV Endocrinol. 2023 Nov;19(2):42-53. doi: 10.17925/EE.2023.19.2.12. Epub 2023 Aug 9.
6
Metastatic pituitary tumors: an institutional case series.转移性垂体瘤:机构病例系列。
Pituitary. 2023 Oct;26(5):561-572. doi: 10.1007/s11102-023-01341-4. Epub 2023 Jul 31.
9
Recent Therapeutic Advances in Pituitary Carcinoma.垂体癌的近期治疗进展
J Immunother Precis Oncol. 2022 Dec 13;6(2):74-83. doi: 10.36401/JIPO-22-25. eCollection 2023 May.
10
The Emerging Role of m6A Modification in Endocrine Cancer.m6A修饰在内分泌癌中的新兴作用
Cancers (Basel). 2023 Feb 6;15(4):1033. doi: 10.3390/cancers15041033.

本文引用的文献

1
Temozolomide in aggressive pituitary adenomas and carcinomas.替莫唑胺治疗侵袭性垂体腺瘤和腺癌。
Clinics (Sao Paulo). 2012;67 Suppl 1(Suppl 1):119-23. doi: 10.6061/clinics/2012(sup01)20.
2
Anti-VEGF therapy in pituitary carcinoma.抗血管内皮生长因子治疗垂体腺癌。
Pituitary. 2012 Sep;15(3):445-9. doi: 10.1007/s11102-011-0346-8.
6
Therapy of aggressive pituitary tumors.侵袭性垂体瘤的治疗。
Expert Opin Pharmacother. 2011 Jul;12(10):1561-70. doi: 10.1517/14656566.2011.568478. Epub 2011 Mar 24.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验